Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Metabolomic Analysis of Body Fluid of Medulloblastoma in Children

Metabolomic Analysis of Body Fluid of Medulloblastoma in Children Based on New Mass Spectrometry and Its Application in Clinical Diagnosis and Recurrence Monitoring

Based on a new mass spectrometry system, body fluid samples were analyzed to verify the role of metabolite analysis in the diagnosis of pediatric medulloblastoma.

Studieoversikt

Status

Ukjent

Detaljert beskrivelse

Screening specific molecular metabolic markers for medulloblastoma after radiotherapy can improve the prediction of clinical diagnosis and prognosis of patients.The purpose of this study is to validate the role of metabolite analysis in the diagnosis of pediatric medulloblastoma based on the analysis of body fluid samples by a new mass spectrometry system.Based on the metabolic markers found by screening, the pathogenic mechanism of metabolic pathway blockade was explained, and the scientific basis for later treatment was put forward.

Studietype

Observasjonsmessig

Registrering (Forventet)

100

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Shanghai
      • Shanghai, Shanghai, Kina, 200092
        • The Department of Radiation Oncology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

3 år og eldre (Barn, Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Different body fluid samples (blood,urine)of patients in each group are estimated to be 100 cases.

Beskrivelse

Inclusion Criteria:

  • The samples are previous biological sample database data;
  • Sample collection time was 2017.05-2019.05;
  • The patient's age is over 3 years old;
  • KPS score ≥50 at the first diagnosis;
  • The patient was a medulloblastoma patient who had received surgical treatment and had not received radiotherapy or chemotherapy before.

Exclusion Criteria:

  • Recurrent patients;
  • Patients suffered from other malignant tumors during radiotherapy;
  • The body fluid samples or related clinical data are not perfect;
  • Storage failure of body fluid samples such as lipid dissolution and hemolysis occurred.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: Case-Control
  • Tidsperspektiver: Retrospektiv

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Metabolic marker(Uracil in Da)
Tidsramme: Changes of expression profiles of specific metabolic markers before and after radiotherapy,up to 3 months.
1. By comparing the expression of small molecule metabolites in body fluids between normal control group and patients with medulloblastoma before radiotherapy, to find specific markers. 2. To evaluate the expression of this metabolic marker in medulloblastoma patients before and after radiotherapy.
Changes of expression profiles of specific metabolic markers before and after radiotherapy,up to 3 months.
Metabolic marker(4-Hydroxyproline in Da)
Tidsramme: Changes of expression profiles of specific metabolic markers before and after radiotherapy,up to 3 months.
1. By comparing the expression of small molecule metabolites in body fluids between normal control group and patients with medulloblastoma before radiotherapy, to find specific markers. 2. To evaluate the expression of this metabolic marker in medulloblastoma patients before and after radiotherapy.
Changes of expression profiles of specific metabolic markers before and after radiotherapy,up to 3 months.
Metabolic marker(Creatine in Da)
Tidsramme: Changes of expression profiles of specific metabolic markers before and after radiotherapy,up to 3 months.
1. By comparing the expression of small molecule metabolites in body fluids between normal control group and patients with medulloblastoma before radiotherapy, to find specific markers. 2. To evaluate the expression of this metabolic marker in medulloblastoma patients before and after radiotherapy.
Changes of expression profiles of specific metabolic markers before and after radiotherapy,up to 3 months.
Metabolic marker(Glutamic acid in Da)
Tidsramme: Changes of expression profiles of specific metabolic markers before and after radiotherapy,up to 3 months.
1. By comparing the expression of small molecule metabolites in body fluids between normal control group and patients with medulloblastoma before radiotherapy, to find specific markers. 2. To evaluate the expression of this metabolic marker in medulloblastoma patients before and after radiotherapy.
Changes of expression profiles of specific metabolic markers before and after radiotherapy,up to 3 months.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Mawei D Jiang, MD, Xin Hua Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. juni 2019

Primær fullføring (Forventet)

1. juni 2022

Studiet fullført (Forventet)

1. juni 2022

Datoer for studieregistrering

Først innsendt

29. juli 2019

Først innsendt som oppfylte QC-kriteriene

20. august 2019

Først lagt ut (Faktiske)

22. august 2019

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

23. september 2019

Siste oppdatering sendt inn som oppfylte QC-kriteriene

19. september 2019

Sist bekreftet

1. juli 2019

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Kliniske studier på Pediatric Medulloblastoma

3
Abonnere